Catalyst Biosciences unveiled details from its early-stage trial to assess the efficacy of its hemophilia B candidate CB 2679d/ISU304 through subcutaneous administration, which showed a linear increase in factor IX levels after six days of dosing, according to topline data presented at the European Association for Hemophilia and Allied Disorders Annual Congress. Continued dosing could achieve more clinically significant results, Catalyst said.
Catalyst Bio reports on preliminary results for hemophilia B candidate
Sign up for Specialty Pharmacy SmartBrief
News affecting the specialty pharmacy industry
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.